Prognostic Roles for Markers for Thyroid Cancer
Vuong HG et al Endocrine Connections Feb 21 2017
Found 35 studies from 18000 patients. TERT Promoter mutation was significantly associated with unfavorable disease free and specific survival. BRAF mutations increased the risk of recurrence, but not cancer mortality. BRAF data shown prognostic value only in short/medium term followup. There was inadequate data on RAS, and RET/PTC for analysis.
Conclusion: Only TERT Promoter mutation can be used as a reliable marker for predicting outcomes. BRAF to assess prognosis is questioned.